Management of Antiviral Resistance in Chronic Hepatitis B

키워드

참고문헌 (65)

1. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
2. Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral", Gastroenterology, 130, pp.678~686 (2006)
3. Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
4. Gordon SC, "Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population", Clin Gastroenterol Hepatol, 12, pp.885~893 (2014)
5. Eun JR, "Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease", J Hepatol, 53, pp.118~125 (2010)
6. Papatheodoridis GV, "Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine", Hepatology, 42, pp.121~129 (2005)
7. Yuen MF, "Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease", Antivir Ther, 12, pp.1295~1303 (2007)
8. Hosaka T, "Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection", Hepatology, 58, pp.98~107 (2013)
9. Wong GL, "Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis", Hepatology, 58, pp.1537~1547 (2013)
10. Lim YS, "Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine", Gastroenterology, 147, pp.152~161 (2014)
11. Wu CY, "Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study", Gastroenterology, 147, pp.143~151.e5 (2014)
12. European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
13. Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update", Clin Gastroenterol Hepatol, 6, pp.1315~1341 (2008)
14. Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
15. Chang TT, "Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 51, pp.422~430 (2010)
16. Kitrinos KM, "No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B", Hepatology, 59, pp.434~442 (2014)
17. Zoulim F, "Management of treatment failure in chronic hepatitis B", J Hepatol, 56(Suppl 1), pp.S112~S122 (2012)
18. Yim HJ, "Evolution of multi-drug resistant hepatitis B virus during sequential therapy", Hepatology, 44, pp.703~712 (2006)
19. Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B", J Hepatol, 44, pp.283~290 (2006)
20. Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy", Hepatology, 43, pp.1385~1391 (2006)
21. Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil", Gut, 55, pp.1488~1495 (2006)
22. Tenney DJ, "Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present", Antimicrob Agents Chemother, 51, pp.902~911 (2007)
23. Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
24. European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
25. Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
26. Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update", Hepatol Int, 6, pp.531~561 (2012)
27. Berg T, "Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronichepatitis B virus infection", Gastroenterology, 139, pp.1207~1217 (2010)
28. Berg T, "Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients", J Hepatol, 60, pp.715~722 (2014)
29. Fung S, "Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 146, pp.980~988.e1 (2014)
30. Patterson SJ, "Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B", Gut, 60, pp.247~254 (2011)
31. Lim YS, "Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure:results of a randomised trial", Gut, 65, pp.852~860 (2016)
32. Lim YS, "Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial", Gut, 65, pp.1042~1051 (2016)
33. Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudineresistant chronic hepatitis B", Gastroenterology, 126, pp.91~101 (2004)
34. Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update", Hepatol Int, 2, pp.263~283 (2008)
35. Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
36. Lampertico P, "Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine-resistant hepatitis B patients", Gastroenterology, 133, pp.1445~1451 (2007)
37. Corsa AC, "No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B", Clin Gastroenterol Hepatol, 12, pp.2106~2112.e1 (2014)
38. Chang TT, "A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients", Gastroenterology, 129, pp.1198~1209 (2005)
39. Sherman M, "Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B", Gastroenterology, 130, pp.2039~2049 (2006)
40. Tenney DJ, "Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine", Antimicrob Agents Chemother, 48, pp.3498~3507 (2004)
41. Villet S, "Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient", J Hepatol, 46, pp.531~538 (2007)
42. Pan CQ, "Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir", J Viral Hepat, 19, pp.213~219 (2012)
43. Yip B, "Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders", Dig Dis Sci, 57, pp.3011~3016 (2012)
44. Leemans WF, "Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir", Eur J Gastroenterol Hepatol, 20, pp.773~777 (2008)
45. Zoulim F, "The safety and efficacy of entecavir and tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure: week 96 results of the ENTEBE study", Hepatology, 60(Suppl 4), pp.314A~315A (2014)
46. Villet S, "Selection of a multiple drug-resistant hepatitis B virus strain in a livertransplanted patient", Gastroenterology, 131, pp.1253~1261 (2006)
47. Villeneuve JP, "Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient", J Hepatol, 39, pp.1085~1089 (2003)
48. Angus P, "Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase", Gastroenterology, 125, pp.292~297 (2003)
49. Heo NY, "Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.", J Hepatol, 53, pp.449~454 (2010)
50. Shim JH, "Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone", Hepatology, 50, pp.1064~1071 (2009)
51. Brunelle MN, "Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir", Hepatology, 41, pp.1391~1398 (2005)
52. Villet S, "Impact of hepatitis B virus rtA181V", T mutants on hepatitis B treatment failure, 2008, pp.48, 747~755
53. Qi X, "In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents", Antivir Ther, 12, pp.355~362 (2007)
54. van Bömmel F, "Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside", nucleotide analogues, 2010, pp.51, 73~80
55. Petersen J, "Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study", J Hepatol, 56, pp.520~526 (2012)
56. Kim GA, "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability", Gut, 63, pp.1325~1332 (2014)
57. Chevaliez S, "Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside", nucleotide analogue therapy: finite treatment duration unlikely, 2013, pp.58, 676~683
58. Pawlotsky JM, "Is hepatitis virus resistance to antiviral drugs a threat", Gastroenterology, 142, pp.1369~1372 (2012)
59. Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
60. World Health Organization, "Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection" (2015), World Health Organization
61. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
62. Korean Association for the Study of Liver, "KASL clinical practice guidelines: management of chronic hepatitis B" (2015), Korean Association for the Study of Liver
63. Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
64. Bartholomeusz A, "Antiviral drug resistance:clinical consequences and molecular aspects", Semin Liver Dis, 26, pp.162~170 (2006)
65. Fournier C, "Antiviral therapy of chronic hepatitis B:prevention of drug resistance", Clin Liver Dis, 11, pp.869~892, ix (2007)

관련 논문AI추천